论文部分内容阅读
目的:评价瑞巴派特与胃复春联用治疗慢性萎缩性胃炎患者的临床疗效。方法:选取2013年2月—2015年8月间治疗的慢性萎缩性胃炎患者180例,根据患者床号,将其分为联用组(90例)和单用组(90例);单用组患者均给予胃复春治疗,联用组患者均给予瑞巴派特与胃复春联用治疗,评价两组患者治疗后的总有效率和不良反应的发生率。结果:联用组患者治疗后的总有效率显著高于对照组(P<0.05)。结论:对于慢性萎缩性胃炎患者采用瑞巴派特与胃复春联用治疗可显著改善患者的临床症状,其疗效优于单用胃复春的治疗。
Objective: To evaluate the clinical efficacy of rebamipide combined with Weifuchun in treating patients with chronic atrophic gastritis. Methods: One hundred and eighty patients with chronic atrophic gastritis who were treated between February 2013 and August 2015 were selected and divided into three groups according to their bed numbers: 90 in combined group and 90 in combined group. All the patients were treated with Weifuchun. The patients in combination group were treated with rebamipide and Weifuchun, and the total effective rate and the incidence of adverse reactions in both groups were evaluated. Results: The total effective rate after treatment in the combined group was significantly higher than that in the control group (P <0.05). Conclusion: The combination of rebamipide and Wei Fu Chun can significantly improve the clinical symptoms of patients with chronic atrophic gastritis, and its curative effect is better than that of Wei We Fu Chun alone.